DOTATATE

DOTA-Tyr3-octreotate, DOTA-TATE, oxodotreotide; Ga-68 DOTATATE = Netspot (kit), gallium Ga 68 dotatate; Lu-177 DOTATATE = Lutathera, lutetium Lu 177 dotatate; related: Cu-64 DOTATATE (Detectnet)

Oncology & imaging

Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates

Note on this profile. DOTATATE products are approved prescription radiopharmaceuticals, handled only in licensed nuclear-medicine departments. This page explains the published science. There is no self-directed or community use; the compound cannot be obtained, stored or administered outside a hospital setting, and nothing here is a dose recommendation.

Summary

Class: Synthetic cyclic octapeptide (octreotate, a Tyr3-Thr8 analogue of octreotide) conjugated via the chelator DOTA to a radioactive metal: gallium-68 (PET imaging) or lutetium-177 (therapy)
Mechanism: The peptide binds somatostatin receptor subtype 2 (SSTR2) on neuroendocrine tumour cells and is internalised; Ga-68 emits positrons that a PET camera detects, while Lu-177 emits short-range beta particles that irradiate the tumour from inside
Routes studied: Intravenous only
Half-life: Gallium-68 physical half-life 68 min; lutetium-177 physical half-life 6.65 days. The peptide itself clears from blood within hours; tumour retention of Lu-177 lasts days
Storage: Hospital radiopharmacy only; Ga-68 is produced on site from a generator and used within hours; Lu-177 shipped at calibrated activity, shielded, used within days of calibration
Regulatory status: Approved medicines (US, EU, UK, AU and others)

Doses are as reported in studies or by the community — never recommendations.

1What it is

DOTATATE is a lab-made relative of octreotide (see octreotide, profile #124), the somatostatin analogue used for decades to treat hormone-secreting tumours. Two small changes to octreotide — a tyrosine at position 3 and a threonine at the C-terminus — give "octreotate", which binds SSTR2 more tightly. A chelator called DOTA is attached so that a radioactive metal can be locked onto the peptide. The same peptide becomes a diagnostic when the metal is gallium-68 and a treatment when it is lutetium-177. This pairing of a scan and a therapy that use the same targeting molecule is what nuclear medicine calls "theranostics".

The approach grew out of Dutch and Swiss work in the 1990s–2000s. Netspot (the Ga-68 kit) was approved in the US in 2016, Lutathera in the EU in 2017 and the US in January 2018. A copper-64 version for PET (Detectnet) followed in 2020.

2How it's thought to work

Targeting. most well-differentiated neuroendocrine tumours (NETs) of the gut, pancreas and lung over-express SSTR2. The octreotate part of the molecule binds that receptor with nanomolar affinity and the receptor-peptide complex is pulled into the cell.

Imaging (Ga-68). positron emission lets a PET/CT scanner map every SSTR2-rich lesion in the body in one session, with far better resolution and sensitivity than the older indium-111 scan (see pentetreotide, #204).

Therapy (Lu-177). beta particles travel roughly 2 mm in tissue, so the energy is deposited mostly in the tumour and its immediate surroundings. Lu-177 also emits a small gamma component that allows post-treatment imaging and dosimetry.

Kidney protection. the peptide is filtered and partly reabsorbed by the kidney; co-infusing the amino acids lysine and arginine competes for that reabsorption and lowers the kidney radiation dose.

A somatostatin analogue carrying a chelator and a radioactive metal. It binds SSTR2 on a neuroendocrine tumour and is pulled inside; gallium-68 makes the lesion visible to a PET scanner, lutetium-177 irradiates it from within.Schematic — not to scale

3What the research shows

Lu-177 DOTATATE in midgut NETs after progression on octreotide

NETTER-1 (n=229) randomised patients with progressive midgut NETs to four cycles of Lu-177 DOTATATE plus octreotide LAR or to high-dose octreotide LAR alone. Progression-free survival at 20 months was 65% vs 11%; hazard ratio for progression or death 0.21 (Strosberg 2017, NEJM). Final overall survival favoured the Lu-177 arm (median 48.0 vs 36.3 months) but did not reach statistical significance, partly because of cross-over (Strosberg 2021, Lancet Oncol). [1][2]

First-line use in higher-grade GEP-NETs

NETTER-2 (n=226) randomised newly diagnosed grade 2–3 (Ki-67 10–55%) gastroenteropancreatic NETs to Lu-177 DOTATATE plus octreotide or high-dose octreotide. Median PFS was 22.8 vs 8.5 months (HR 0.28) and objective response 43% vs 9% (Singh 2024, Lancet). This moved the therapy into first-line discussion for faster-growing tumours. [3]

Graded A/B

Ga-68 DOTATATE PET for NET detection and staging

Prospective comparisons report sensitivity above 90% and detection of substantially more lesions than In-111 pentetreotide SPECT or CT alone (Sadowski 2016, J Clin Oncol — 131 patients, prospective; Deppen 2016, J Nucl Med meta-analysis). Grade "A/B" because diagnostic accuracy studies are prospective but not randomised. [4][5]

Paediatric use

NETTER-P, a small single-arm study in adolescents, supported US approval for patients aged 12 and older in April 2024 (regulatory summary; † publication status).

Other SSTR-positive tumours (paraganglioma, pheochromocytoma, meningioma, medullary thyroid)

Case series and small prospective studies report responses; none of these are approved indications.

4Reported side effects and interactions

Literature-reported

Literature (Lu-177 DOTATATE). nausea and vomiting during infusion (largely from the amino-acid solution, ~60%), fatigue, transient drops in white cells, platelets and haemoglobin; grade 3–4 haematological toxicity in roughly 10%. Delayed myelodysplastic syndrome or acute leukaemia in about 2–3% of patients, typically 1–3 years after treatment. Kidney function decline is uncommon with amino-acid protection but is monitored for life. Hormonal "flare" (carcinoid crisis) can occur in patients with functional tumours when cells release stored hormone; prophylactic octreotide is used. Radiation exposure to contacts requires hygiene precautions for a few days.

Literature (Ga-68 DOTATATE). essentially no adverse effects beyond the small radiation dose; occasional nausea or injection-site discomfort.

Community-reported

Community use. essentially none documented. These are hospital-only radiopharmaceuticals.

Theoretical. fertility effects from gonadal radiation dose; contraception is recommended during and for months after therapy.

Interactions. long-acting somatostatin analogues (octreotide LAR, lanreotide) compete for the same receptor and are paused before imaging and therapy (short-acting octreotide stopped 24 h before, long-acting 4–6 weeks before, per label). Glucocorticoids may reduce SSTR2 expression. Nephrotoxic drugs add to kidney risk.

Markers researchers commonly monitor

Taken from the Lutathera label and NETTER trial protocols:

Marker	Why it's watched
Full blood count (CBC) before each cycle and periodically for years	the main toxicity is on bone marrow; also screens for the delayed MDS/leukaemia signal.
Creatinine, eGFR and urinalysis	the kidney is the dose-limiting organ; checked before every cycle and long-term.
Liver enzymes and bilirubin	hepatic metastases are common and liver irradiation adds to injury risk.
Chromogranin A and 5-HIAA (urine or plasma)	tumour markers used to follow response in functional tumours, with the caveat that they are imperfect.
Hormone levels relevant to the tumour (insulin, gastrin, glucagon, VIP)	functional tumours can flare during treatment.
Ga-68 DOTATATE PET itself	the scan confirms receptor expression (eligibility) and is repeated to assess response.
Pregnancy test before each cycle in people who can become pregnant

Free for everyone. Safety information is never behind a paywall.

5Reconstitution and handling

Not applicable to individuals. Netspot is supplied as a kit that a hospital radiopharmacy labels with Ga-68 eluted from a germanium/gallium generator, then quality-tests before injection. Lutathera arrives as a ready-to-use sterile solution at a calibrated activity and is administered through shielded tubing by nuclear-medicine staff. No calculator link is provided for this compound.

6Commonly studied alongside

Octreotide (#124) and lanreotide (long-acting SSAs given between cycles); DOTATOC (#202, the closest alternative peptide); pentetreotide (#204, the legacy scan it replaced); satoreotide (#205, the antagonist being tested as a successor); everolimus and sunitinib as comparator or sequence therapies.

Informational cross-links. Not stack recommendations.

7Regulatory status by region

Region	Status (checked —)
United States	Netspot (Ga-68 dotatate kit) FDA-approved 2016; Lutathera FDA-approved January 2018 for SSTR-positive GEP-NETs, extended to patients ≥12 years in April 2024; Detectnet (Cu-64 dotatate) approved 2020
European Union	Lutathera EMA-authorised September 2017 for unresectable or metastatic progressive SSTR-positive GEP-NETs. Ga-68 DOTATATE is widely used but mostly under national or hospital-exemption rules; SomaKit TOC (DOTATOC) is the EU-authorised Ga-68 kit †
United Kingdom	Lutathera MHRA-licensed (carried over from EU authorisation); Ga-68 DOTATATE PET available in NHS centres under specials/hospital production †
Australia	Lutathera TGA-registered; Ga-68 DOTATATE PET widely available and MBS-funded under local production †
South Africa	Lu-177 DOTATATE therapy and Ga-68 DOTATATE PET available at a small number of academic centres; registration status of branded products †
Sport (WADA)	Not listed; a hospital cancer treatment with no performance relevance

8Open questions

How best to sequence Lu-177 DOTATATE against everolimus, sunitinib and chemotherapy, and whether retreatment after relapse is safe and effective.
Whether alpha-emitting versions (Ac-225 DOTATATE) improve outcomes in tumours resistant to beta therapy.
The true long-term incidence of therapy-related myeloid neoplasms and how to predict who is at risk.
Whether the overall-survival benefit seen as a trend in NETTER-1 will be confirmed in NETTER-2 with longer follow-up.

9References

1Strosberg J et al. (2017). Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors (NETTER-1). N Engl J Med. PubMed · DOI
2Strosberg JR et al. (2021). 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results. Lancet Oncol. PubMed · DOI
3Singh S et al. (2024). [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated gastroenteropancreatic neuroendocrine tumours (NETTER-2). Lancet. PubMed · DOI
4Sadowski SM et al. (2016). Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol. PubMed · DOI
5Deppen SA et al. (2016). Safety and efficacy of 68Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. J Nucl Med. PubMed · DOI
6Kwekkeboom DJ et al. (2008). Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. PubMed · DOI
7FDA. Lutathera (lutetium Lu 177 dotatate) prescribing information; Netspot (kit for the preparation of gallium Ga 68 dotatate) prescribing information. PubMed

References are being resolved to PubMed/DOI identifiers; links search PubMed for the citation until then.

† Being confirmed by our reviewers against current sources.

10Community

forum threads →

community protocols include this →

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

31 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.